Chemo's hidden toll: new study tracks hair, skin, and nail changes in breast cancer patients
NCT ID NCT02530177
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 546 women with non-metastatic breast cancer to see how chemotherapy or endocrine therapy affects their hair, skin, and nails. Researchers will use clinical exams, photos, and questionnaires to track changes and identify who is most at risk. The goal is to better understand these side effects and improve how doctors prevent and treat them.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict and manage chemotherapy-related hair, skin, and nail side effects, improving quality of life for breast cancer patients.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test any new therapy, and results may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 546 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2015
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
MSKCC clinics
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women newly diagnosed with non-metastatic breast cancer (stage 0-III, any receptor type) at the time of starting chemotherapy (dd-AC-T, CMF, Newer Combination Regimens) or endocrine therapy (tamoxifen, anastrozole, letrozole, exemestane) * Women ≥ 18 years at the time of enrollment into the study * Able to communicate in English and participate in the informed consent process * Able to comply with the follow-up visits, assessments, answering questionnaires Exclusion Criteria: * Metastatic breast cancer * Follow-up care/visits not scheduled at MSKCC * Any current alopecia especially due to an active scalp and/or hair disorder (e.g. alopecia areata), or a pre-existing condition with sequelae (e.g. scarring alopecia) * Currently active or uncontrolled medical condition \[e.g. thyroid disorder, auto-immune connective tissue disease (e.g. SLE), BMT complications (GVHD)\] or medication intake (e.g. HRT), affecting scalp hair * Prior systemic treatment for any malignancy * Active secondary cancer requiring cytotoxic chemotherapy * Planned (or a history of) radiation therapy to the head * Vulnerable populations \[e.g. decisionally impaired (cognitive, psychiatric), terminally ill, prisoners\], or patients who, in the opinion of the investigator have a condition that precludes their ability to provide an informed consent * Men Volunteer Inclusion Criteria: * Post menopausal women, with menopausal status defined as (per self report): * Bilateral salpingo-oophorectomy independent of age * If natural menopause, age ≥ 50 with cessation of menses for at least 12 months * Or premenopausal women with premenopausal status defined as \<53 years of age with no cessation of menses * Able to communicate in English and participate in the informed consent process * Able to comply with the baseline assessments and answering questionnaires * Women \>/= 18 years at the time of enrollment into the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non metastatic breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new program aims to ease cancer survivors' fear of recurrence
- Could a support program ease the side effects of breast cancer hormone therapy?
- App aims to get breast cancer patients moving during chemo
- Exercise after chemo: could a simple walking program protect your heart?
- Can a meaning-centered group help breast cancer survivors find purpose?
- Could a pill shield hearts from chemo damage? new study investigates